The Centers for Medicare and Medicaid Services should crack down on all private health plans that engage in the practice of covering drugs but then avoiding some of the cost sharing protections established by the Affordable Care Act by designating the drugs as “non essential” benefits the HIV Plus Hepatitis Policy Institute urged the agency in 8 January comments.
‘Essential Benefit’ Drug Coverage Protections Is Next Priority For Patient Group Behind Copay Accumulator Victory
HIV+Hepatitis Policy Institute provides CMS with a long list of plan sponsors and vendors that appear to be engaged in the practice, which the group argues circumvents the cost sharing protections provided by the Affordable Care Act for hundreds of drugs.
